Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

(MedPage Today) -- Patients with metastatic urothelial carcinoma who achieved a complete response after more than 8.5 months of single-agent enfortumab vedotin (Padcev) were able to be off treatment for over 2 years before needing to restart therapy...